BC Innovations | Dec 11, 2014
Targets & Mechanisms

Lysin in wait

As researchers chase new ways to combat antibiotic resistance, two companies are tackling the problem with anti-infectives based on phage lysins-enzymes that kill bacteria selectively and are not prone to bacterial resistance. Micreos B.V. and...
BioCentury | Mar 11, 2013
Product Development

Neomics' new tricks

Neomics Co. Ltd. is leveraging previously unknown functions of aminoacyl tRNA synthetases and their interacting proteins to build a pipeline of therapeutics and diagnostics for cancer. The most advanced program focuses on detecting and targeting...
BioCentury | Jul 4, 2011
Emerging Company Profile

ContraFect: Bringing down the walls

ContraFect Corp. believes a class of enzymes called lysins, which break open the cell walls of Gram-positive bacteria, could enhance the efficacy of low doses of conventional antibiotics while avoiding side effects and the development...
BC Innovations | Jan 6, 2011
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus Not applicable A study in mice suggests that chimeric lysin for staphylococci (ClyS) could help treat staphylococcus infections. In a mouse model of...
BC Innovations | Apr 10, 2008
Targets & Mechanisms

Staph: The NOse Have It

A paper published in Science sheds light on why Staphylococcus aureus so successfully colonizes nasal passages and points to a new target, lactate dehydrogenase , for blocking this pathogen before it can cause systemic infection. 1...
BC Week In Review | Dec 10, 2007
Clinical News

Phynova preclinical data

In vitro, PYN6 inhibited 30 common strains of MRSA bacteria at doses that were 10-fold less the topical antibiotic mupirocin. PYN6, a plant-derived antibacterial agent, also had activity against the Propionibacterium acnes organism. Data were...
BioCentury | Aug 14, 2006
Tools & Techniques

More pep against infection

Ceragenins are cationic steroid antibiotics (CSAs) that are small molecule mimics of antimicrobial peptides. Active against a broad range of Gram-positive and -negative bacteria, they are being developed by Ceragenix Pharmaceuticals Inc. as anti-infective medical...
BC Week In Review | Jul 24, 2006
Clinical News

REP8839: Phase I started

RDYN began a placebo-controlled Phase I trial of REP8839 in combination with topical antibiotic mupirocin in 110 healthy volunteers. The company expects to complete up to 3 Phase I trials of the combination in the...
BioCentury | Sep 19, 2005

Ebb & Flow

FDA's accidental posting of briefing documents for Celgene's Revlimid a day ahead of schedule gave alert investors an afternoon of arbitrage last Monday. Typically, the agency posts its clinical and statistical reviews of a compound...
BC Week In Review | Jun 17, 2002
Clinical News

Bactroban Nasal mupirocin ointment: Marketed to eradicate nasal colonization with methicillin-resistant S. aureus

In a double-blind, placebo-controlled MARS trial in 3,864 evaluable patients, preoperative intranasal application of mupirocin did not significantly reduce the rate of S. aureus surgical site infections overall (2.3% and 2.4% for Bactroban and placebo)...
Items per page:
1 - 10 of 15